KPV: What It Is and What It Does

What KPV is

KPV is a very small peptide — just three amino acids (lysine-proline-valine) — taken from the tail end of a natural hormone called alpha-MSH. It is supplied as an analytical-grade reference material for laboratory research.

Where it comes from

KPV takes its name from its three amino acids: lysine (K), proline (P), and valine (V). It is the C-terminal tail (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone best known for controlling skin pigment. Researchers found that much of alpha-MSH's separate anti-inflammatory activity survives in this tiny three-amino-acid fragment, even without the parts of the hormone that drive pigmentation. That combination of small size and retained activity is what made KPV an interesting tool in inflammation research.

What it does — in plain terms

KPV's claim to fame in research is calming inflammation. When tissue gets red, swollen, and irritated, cells are essentially shouting 'emergency' — KPV appears to turn that shouting down. Because of that, labs mostly study it in models of gut inflammation and irritated skin, where an 'off switch' for an over-active immune response is useful. Its very small size is part of the interest, because tiny peptides can reach places larger ones can't.

How it works

KPV is the very end of the alpha-MSH hormone, and its appeal in research is that this tiny fragment appears to keep much of the parent hormone's ability to calm inflammation. Rather than acting only on the surface melanocortin receptors that alpha-MSH is known for, evidence suggests KPV can enter cells and act on the inflammatory machinery more directly, which is unusual for such a small peptide.

A central mechanism in the gut literature is uptake through PepT1, a transporter that carries small peptides into intestinal cells and is more abundant in inflamed gut lining. Once inside, KPV is described as interfering with pro-inflammatory signaling, notably the NF-kB pathway, which lowers the output of inflammatory messengers. This helps explain why colitis and other gut-inflammation models feature so heavily in the research.

A large share of the KPV literature is actually about delivery. Because tiny peptides are fragile and quickly broken down, many studies wrap KPV in nanoparticles or hydrogels to protect it and steer it to the colon or a wound surface. All of this work is preclinical (cell and animal models), so it describes what researchers observe in the laboratory rather than established effects in people.

What the research shows

KPV's research is notably concentrated: most of it centers on calming inflammation, above all in the gut, with a strong secondary theme of how to deliver such a small, fragile peptide effectively. It is important to be clear that this evidence is essentially all preclinical, from animal and cell studies, with no substantial human trials to date. With that in mind, here is what some of the published work actually reports.

• Inflammatory Bowel Diseases, 2008 — reported that the KPV tripeptide reduced inflammation in an animal model of inflammatory bowel disease.
• Biomaterials Science, 2021 — delivered KPV in a hydrogel and examined its effect on oral mucositis (inflammation of the mouth lining) in an animal model.
• Advances in Experimental Medicine and Biology, 2010 — reviewed the anti-inflammatory effects of alpha-MSH-related peptides, the hormone family that KPV is derived from.
• Gastroenterology, 2008 — examined how the KPV tripeptide is taken up by intestinal cells through the PepT1 transporter and reduces inflammatory signaling in the gut.
• Molecular Therapy, 2017 — used nanoparticles to deliver KPV and studied its effect in a laboratory model of ulcerative colitis.
• Gastroenterology, 2010 — developed colon-targeted nanoparticles carrying KPV and tested them in a mouse model of colitis.
• ACS Biomaterials Science & Engineering, 2021 — formulated a hydrogel to stabilize and release KPV, testing it in a rat model of ulcerative colitis.
• Cellular and Molecular Gastroenterology and Hepatology, 2016 — studied the PepT1 transporter and KPV in a mouse model of colitis-associated cancer, linking peptide uptake to reduced inflammation.
• PLOS One, 2018 — made structural modifications to the KPV tripeptide to study how its shape relates to stability and anti-inflammatory activity.
• Experimental Eye Research, 2006 — examined an alpha-MSH tripeptide (KPV) in corneal wound healing at the surface of the eye.

What KPV is studied for

Gut inflammation (colitis and IBD models). The flagship area. Animal and cell studies of colitis and inflammatory bowel disease repeatedly describe KPV lowering inflammatory signaling in the intestinal lining.

How KPV enters cells and quiets inflammation. A distinctive mechanism is uptake via the PepT1 transporter, followed by interference with pro-inflammatory pathways such as NF-kB, of interest because it suggests the peptide acts inside the cell, not just at surface receptors.

Skin and surface healing. Beyond the gut, KPV is examined in irritated tissue such as the mouth lining and the surface of the eye, where an anti-inflammatory, healing-supportive signal is useful.

Peptide delivery and formulation. Much of the literature focuses on protecting this fragile tripeptide with nanoparticles or hydrogels so it survives long enough to reach an inflamed site such as the colon.

Storage & handling

As a lyophilized (freeze-dried) powder, KPV reference material is most stable kept cold and dark, refrigerated for short-term storage or frozen for longer holds. Once reconstituted with bacteriostatic water it should be refrigerated at roughly 2-8 °C, kept out of light, and protected from repeated freeze-thaw cycles; as a small tripeptide it is easily degraded, so careful handling matters. See the reconstitution reference below for the concentration math.

Reconstitution reference

Standard laboratory reconstitution volumes for KPV, from the VNG Reconstitution Sheet. See the full reconstitution guide for the method and concentration math.